
Leqembi Best at Fighting Alzheimer’s in Men
McGill University researchers found Leqembi to be even more effective, in males than females, at fighting Alzheimer’s.
McGill University researchers found Leqembi to be even more effective, in males than females, at fighting Alzheimer’s.
The new Alzheimer’s antibodies, Leqembi and Kisunla, work better on some people than others. A cutting-edge technique called spatial transcriptomics may help figure out how to make them work better for everybody.
ARTICLE + VIDEO INFOMMERCIAL: Namazaric for dementia comes in a convenient, extended-release capsule. It conveniently combines today’s 2 most popular drugs for Alzheimer’s. Learn about easy-to-manage Namazaric.
Dementia’s cholinesterase inhibitors can affect trips to the bathroom, according to researchers in Houston, Texas. Learn more if you take donepezil, rivastigmine or galantamine. (Brand names Adlarity, Aricept, Ebixa, Exelon, Namzaric, Razadyne)
A new analysis of the benefits of these Alzheimer’s treatments scores the days and ways patients succeed in living independently.
The EMA has announced its schedule for reviewing the Alzheimer’s drug Leqembi (lecanemab) for use in Europe. Meanwhile, the U.S. FDA, which already approved the drug, is moving ahead with a new version that doses Leqembi in a better, more convenient fashion for those taking the drug over the long run.
Learn about 2025’s newly approved or potential Alzheimer’s drugs. These include Leqembi, Kisunla, Remternetug, Semaglutide, Trontinemab and Bepranemab.
Leqembi and Kisunla are the new Alzheimer’s immunotherapies. A loss of brain volume associated with these immunotherapies may be caused by the removal of amyloid plaques, rather than the loss of neurons or brain tissue. A new study sheds light on what’s going on.
Europe originally said Lecanemab (Brand-name Leqembi) was too risky to approve. Now they are recommending marketing it. Why the change of heart?
The European Medicines Agency (EMA) recommended approving Leqembi® (generic lecanemab) for Alzheimer’s. Originally skeptics, learn how the “Clarity AD” trial helped change their mind.
MEMORY PROBLEMS, an early sign of Alzheimer’s, are linked to glucose sugar deprivation in brain cells. So is diabetes, a well-known Alzheimer’s risk factor. How strongly connected is the Alzheimer’s-Sugar-Diabetes triangle?
TEEPA SNOW CARE VIDEO: Vascular dementia poses unique challenges to caregivers. Learn how vascular dementia differs from Alzheimer’s. See how to make life better, both for you and the one for whom you care.
People with dementia deserve dignity and have rights. Where do we draw the line between encouraging personal choices versus following what caregivers think is best? See Dr. Murray Raskin & Dr. Linda Teri offer experienced tips.
Three important dementia studies focus on HS-AGING, a type of dementia almost as common as Alzheimer’s in the 85+ group. Yet few people have heard of it. Why? What makes it different?
An intriguing study of 120 grandmothers might surprise you. Doctors know socially engaged people have better cognition and less dementia. But can a person get too much of a good thing? What’s the right balance?
Enjoy this great duet between a musician with dementia and his son. A triumph of spirit over Alzheimer’s! Sing-a-long if you like!
It looks like a sneeze cannot give anyone Alzheimer’s. While Alzheimer’s abnormal disease proteins do spread from cell-to-cell, they are not “infectious”. Check out the facts.
No spam, only news and updates.